{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:25:27Z","timestamp":1757611527899,"version":"3.44.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.canrad.2025.104684","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T21:17:57Z","timestamp":1753910277000},"page":"104684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypofractionated radiotherapy in the management of bladder cancer"],"prefix":"10.1016","volume":"29","author":[{"given":"Alice","family":"Blache","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9620-840X","authenticated-orcid":false,"given":"Constance","family":"Huck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9rane","family":"Achard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Coutte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Galienne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.canrad.2025.104684_bib0135","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"year":"2020","series-title":"GLOBOCAN 2020: cancer incidence and mortality worldwide","key":"10.1016\/j.canrad.2025.104684_bib0140"},{"issue":"14","key":"10.1016\/j.canrad.2025.104684_bib0145","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.purol.2022.08.005","article-title":"[Complications in urological surgery: bladder surgery]","volume":"32","author":"Pignot","year":"2022","journal-title":"Prog Urol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104684_bib0150","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"year":"2024","series-title":"NCCN Clinical Practice Guidelines in Oncology: bladder cancer","key":"10.1016\/j.canrad.2025.104684_bib0155"},{"year":"2015","series-title":"Bladder cancer: diagnosis and management","key":"10.1016\/j.canrad.2025.104684_bib0160"},{"issue":"5","key":"10.1016\/j.canrad.2025.104684_bib0165","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"issue":"16","key":"10.1016\/j.canrad.2025.104684_bib0170","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.canrad.2025.104684_bib0175","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104684_bib0180","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104684_bib0190","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ijrobp.2025.03.018","article-title":"Online adaptive radiation therapy for bladder preservation: transitioning to hypofractionation","volume":"122","author":"Krishnan","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104684_bib0185","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2024.09.006","article-title":"Dose-escalated adaptive radiotherapy for bladder cancer: results of the phase 2 RAIDER randomised controlled trial","volume":"87","author":"Huddart","year":"2025","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104684_bib0195","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 Trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104684_bib0200","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1200\/JCO.2010.31.5721","article-title":"Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer","volume":"29","author":"Choudhury","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104684_bib0205","doi-asserted-by":"crossref","first-page":"104557","DOI":"10.1016\/j.critrevonc.2024.104557","article-title":"Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: a systematic review of prospective trials","volume":"205","author":"Baudelin","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.canrad.2025.104684_bib0210","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1038\/sj.bjc.6601852","article-title":"Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer","volume":"90","author":"Hussain","year":"2004","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.canrad.2025.104684_bib0215","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2016.11.040","article-title":"Tolerability of concurrent chemoradiation therapy with gemcitabine (GemX), with and without prior neoadjuvant chemotherapy, in muscle invasive bladder cancer","volume":"97","author":"Thompson","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.canrad.2025.104684_bib0220","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2005.09.023","article-title":"Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose?","volume":"64","author":"Pos","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.canrad.2025.104684_bib0225","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0167-8140(91)90033-D","article-title":"Dose fractionation and tumour repopulation in radiotherapy for bladder cancer","volume":"21","author":"Maciejewski","year":"1991","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104684_bib0230","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jmir.2016.10.014","article-title":"Adaptive radiotherapy for bladder cancer\u00a0\u2013\u00a0a systematic review","volume":"48","author":"Kong","year":"2017","journal-title":"J Med Imaging Radiat Sci"},{"key":"10.1016\/j.canrad.2025.104684_bib0235","doi-asserted-by":"crossref","first-page":"637591","DOI":"10.3389\/fonc.2021.637591","article-title":"MR-guided adaptive radiotherapy for bladder cancer","volume":"11","author":"Hijab","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104684_bib0240","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ijrobp.2013.11.211","article-title":"Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation","volume":"88","author":"Goldsmith","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104684_bib0245","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.ju.0000102302.26806.fb","article-title":"Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study","volume":"171","author":"Leissner","year":"2004","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104684_bib0250","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/j.ijrobp.2011.05.051","article-title":"Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience","volume":"82","author":"Tunio","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.canrad.2025.104684_bib0255","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.23.02718","article-title":"Benefit of whole-pelvis radiation for patients with muscle-invasive bladder cancer: an inverse probability treatment weighted analysis","volume":"43","author":"Marcq","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104684_bib0260","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2021.06.011","article-title":"Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder","volume":"161","author":"Khalifa","year":"2021","journal-title":"Radiother Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:41:16Z","timestamp":1756932076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825001003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":26,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1278321825001003"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104684","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated radiotherapy in the management of bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104684"}}